Related Experiment Videos
[Biological assessment criteria during antagonist protocols].
1Centre Hospitalier Intercommunal Jean-Rostand, Sèvres, France.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|January 12, 2005
Summary
Gonadotropin-releasing hormone (GnRH) antagonists offer new options for preventing luteinizing hormone surges during controlled ovarian stimulation. Studies show no difference in oocyte maturation or fertilization rates compared to GnRH agonists.
Area of Science:
- Reproductive endocrinology and infertility treatments.
- Assisted reproductive technologies (ART).
Context:
- Historically, gonadotropin-releasing hormone (GnRH) agonists were the sole method for preventing premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation.
- The introduction of GnRH antagonists provides clinicians with alternative therapeutic options.
Purpose:
- To review and summarize existing studies on oocyte quality and fertilization rates in in vitro fertilization (IVF) cycles utilizing GnRH antagonists.
- To compare the efficacy of GnRH antagonists versus GnRH agonists in ART.
Summary:
- Clinical trials indicate that GnRH antagonist regimens may be associated with slightly lower pregnancy and implantation rates compared to traditional GnRH agonist protocols.
- However, current research demonstrates no significant difference between GnRH agonists and antagonists regarding oocyte maturation and fertilization rates.
- Data on oocyte morphology anomalies in cycles using GnRH antagonists remain limited.
Impact:
- Provides a comparative analysis of GnRH antagonists and agonists in IVF, focusing on oocyte maturation and fertilization.
- Highlights the need for further research into oocyte morphology and long-term outcomes with GnRH antagonists.
- Informs clinical decision-making regarding the selection of ovulation induction protocols in assisted reproduction.